157 related articles for article (PubMed ID: 9881093)
1. Design and synthesis of nonpeptide angiotensin II receptor antagonists featuring acyclic imidazole-mimicking structural units.
Angiolini M; Belvisi L; Poma D; Salimbeni A; Sciammetta N; Scolastico C
Bioorg Med Chem; 1998 Nov; 6(11):2013-27. PubMed ID: 9881093
[TBL] [Abstract][Full Text] [Related]
2. The conformation and activity relationship of fused analogs of DuP753.
Yoo SE; Shin YA; Lee SH; Kim NJ
Bioorg Med Chem; 1995 Mar; 3(3):289-95. PubMed ID: 7606390
[TBL] [Abstract][Full Text] [Related]
3. Transposition of the imidazole ring substituents of angiotensin mimetics related to Losartan.
Smith JR; Wahhab A; Moore D; Ganter RC; Moore GJ
Drug Des Discov; 1994 Nov; 12(2):113-9. PubMed ID: 9116166
[TBL] [Abstract][Full Text] [Related]
4. A 3D QSAR CoMFA study of non-peptide angiotensin II receptor antagonists.
Belvisi L; Bravi G; Catalano G; Mabilia M; Salimbeni A; Scolastico C
J Comput Aided Mol Des; 1996 Dec; 10(6):567-82. PubMed ID: 9007690
[TBL] [Abstract][Full Text] [Related]
5. Nonpeptide angiotensin II receptor antagonists: synthetic and computational chemistry of N-[[4-[2-(2H-tetrazol-5-yl)-1-cycloalken-1- yl]phenyl]methyl]imidazole derivatives and their in vitro activity.
Lin HS; Rampersaud AA; Zimmerman K; Steinberg MI; Boyd DB
J Med Chem; 1992 Jul; 35(14):2658-67. PubMed ID: 1635064
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic anion transporter 4.
Yamashita F; Ohtani H; Koyabu N; Ushigome F; Satoh H; Murakami H; Uchiumi T; Nakamura T; Kuwano M; Tsujimoto M; Sawada Y
J Pharm Pharmacol; 2006 Nov; 58(11):1499-505. PubMed ID: 17132213
[TBL] [Abstract][Full Text] [Related]
7. Rationale for the chemical development of angiotensin II receptor antagonists.
Wexler RR; Carini DJ; Duncia JV; Johnson AL; Wells GJ; Chiu AT; Wong PC; Timmermans PB
Am J Hypertens; 1992 Dec; 5(12 Pt 2):209S-220S. PubMed ID: 1290616
[TBL] [Abstract][Full Text] [Related]
8. Studies on nonpeptide angiotensin II receptor antagonists. IV. Synthesis and biological evaluation of 4-acrylamide-1H-imidazole derivatives.
Okazaki T; Watanabe T; Kikuchi K; Suga A; Shibasaki M; Fujimori A; Inagaki O; Yanagisawa I
Chem Pharm Bull (Tokyo); 1998 Jun; 46(6):973-81. PubMed ID: 9658576
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade.
Ohlstein EH; Brooks DP; Feuerstein GZ; Ruffolo RR
Pharmacology; 1997 Nov; 55(5):244-51. PubMed ID: 9399334
[TBL] [Abstract][Full Text] [Related]
10. Diphenylpropionic acids as new AT1 selective angiotensin II antagonists.
Almansa C; Gómez LA; Cavalcanti FL; de Arriba AF; Rodríguez R; Carceller E; García-Rafanell J; Forn J
J Med Chem; 1996 May; 39(11):2197-206. PubMed ID: 8667363
[TBL] [Abstract][Full Text] [Related]
11. Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives.
Carini DJ; Duncia JV; Aldrich PE; Chiu AT; Johnson AL; Pierce ME; Price WA; Santella JB; Wells GJ; Wexler RR
J Med Chem; 1991 Aug; 34(8):2525-47. PubMed ID: 1875348
[TBL] [Abstract][Full Text] [Related]
12. [Losartan. The first non-peptide angiotensin II receptor antagonist for treatment of hypertension].
Ibsen H; Rasmussen S; Slatanach R
Ugeskr Laeger; 1996 Jun; 158(26):3798-802. PubMed ID: 8686080
[No Abstract] [Full Text] [Related]
13. Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan.
Shetty SS; DelGrande D
J Pharmacol Exp Ther; 2000 Jul; 294(1):179-86. PubMed ID: 10871310
[TBL] [Abstract][Full Text] [Related]
14. [Nonpeptide angiotensin II receptor antagonists].
Nishikawa K
Tanpakushitsu Kakusan Koso; 1993 Aug; 38(11):1873-80. PubMed ID: 8210431
[No Abstract] [Full Text] [Related]
15. [Molecular biology of angiotensin II receptor and clinical application of the antagonist].
Hiwada K
Nihon Naika Gakkai Zasshi; 1994 Jan; 83(1):143-8. PubMed ID: 9132445
[No Abstract] [Full Text] [Related]
16. [Nonpeptide angiotensin II antagonists].
Shionoiri H; Takasaki I; Sugimoto K; Minamisawa K
Nihon Rinsho; 1992 Apr; 50 Suppl():753-63. PubMed ID: 1635263
[No Abstract] [Full Text] [Related]
17. Efforts to understand the molecular basis of hypertension through drug:membrane interactions.
Mavromoustakos T; Zoumpoulakis P; Kyrikou I; Zoga A; Siapi E; Zervou M; Daliani I; Dimitriou D; Pitsas A; Kamoutsis C; Laggner P
Curr Top Med Chem; 2004; 4(4):445-59. PubMed ID: 14965311
[TBL] [Abstract][Full Text] [Related]
18. Binding of valsartan to mammalian angiotensin AT1 receptors.
de Gasparo M; Whitebread S
Regul Pept; 1995 Nov; 59(3):303-11. PubMed ID: 8577935
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and study of a cyclic angiotensin II antagonist analogue reveals the role of pi*--pi* interactions in the C-terminal aromatic residue for agonist activity and its structure resemblance with AT(1) non-peptide antagonists.
Polevaya L; Mavromoustakos T; Zoumboulakis P; Golic Grdadolnik S; Roumelioti P; Giatas N; Mutule I; Keivish T; Vlahakos DV; Iliodromitis EK; Kremastinos DT; Matsoukas J
Bioorg Med Chem; 2001 Jun; 9(6):1639-47. PubMed ID: 11408184
[TBL] [Abstract][Full Text] [Related]
20. Molecular shape comparison of angiotensin II receptor antagonists.
Masek BB; Merchant A; Matthew JB
J Med Chem; 1993 Apr; 36(9):1230-8. PubMed ID: 8487259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
